Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

Clinical Infectious Diseases

Volumn 39, Issue 8, 2004, Pages 1095-1103

  Walsh, Douglas S ^a,d   Wilairatana, Polrat ^b   Tang, Douglas B ^c   Heppner Jr , D Gray ^a   Brewer, Thomas G ^a   Krudsood, Srivicha ^b   Silachamroon, Udomsak ^b   Phumratanaprapin, Weerapong ^b   Siriyanonda, Duangsuda ^a   Looareesuwan, Sornchai ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; METHEMOGLOBIN; PRIMAQUINE; TAFENOQUINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALARIA; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PLASMODIUM VIVAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; VERTIGO;

ADOLESCENT; ADULT; AMINOQUINOLINES; ANTIMALARIALS; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALARIA, VIVAX; MALE; METHEMOGLOBIN; MIDDLE AGED; PRIMAQUINE; RECURRENCE; RISK; TIME FACTORS;

EID: 19944433208     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424508     Document Type: Article

References (23)

1. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55:243-9.
2. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull World Health Organ 1981; 59:391-5
3. Looareesuwan S, Buchachart K, Wilairatana P, et al. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 1997; 91:939-43.
4. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of sub-therapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65:471-6.
5. Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000; 62:393-5.
6. Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized doseranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 1999; 180:1282-7.
7. Peters W. The evolution of tafenoquine - antimalarial for a new millennium? J R Soc Med 1999; 92:345-52.
8. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 1998; 42:1293-4.
9. Brueckner RP, Lasseter K, Lin E, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58:645-9.
10. Cooper RD, Milhous WK, Rieckmann KH. The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Trans R Soc Trop Med Hyg 1994; 88:691-2.
11. Fisk TL, Millet P, Collins WE, Nguyen-Dinh P. In vitro activity of antimalarial compounds on the exoerythrocytic stages of Plasmodium cynomolgi and P. knowlesi. Am J Trop Med Hyg 1989; 40:235-9.
12. Obaldia N, Rossan RN, Cooper RD, et al. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 1997; 56:508-10.
13. Puri SK, Dutta GP. Blood schizontocidal activity of WR 238605 (tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. Acta Trop 2003; 86:35-40.
14. Kocisko DA, Walsh DS, Eamsila C, Edstein MD. Measurement of tafenoquine (WR 238605) in human plasma and venous and capillary blood by high-pressure liquid chromatography. Ther Drug Monit 2000; 22:184-9.
15. Ederer F, Mantel N. Confidence limits on the ratio of two Poisson variables. Am J Epidemiol 1974; 100:165-7.
16. Altman DG. Practical statistics for medical research. New York: Chapman and Hall, 1991.
17. Lee ET. Nonparametric methods for comparing survival duration. In: Statistical methods for survival analysis data. 2nd ed. New York: Wiley, 1992:109-12.
18. Lukens JN. Methemoglobinemia and other disorders accompanied by cyanosis. In: Lee GR, ed. Wintrobe's clinical hematology. 9th ed. Philadelphia: Lea and Febiger, 1993:1262-71.
19. Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994; 88:218-9.
20. Nasveld P, Kitchener S, Edstein M, Rieckmann K. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 2002; 96:683-4.
21. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341:96-100.
22. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001; 33:1968-74.
23. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003; 36:541-9.